Duchenne Muscular Dystrophy Dmd — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for duchenne muscular dystrophy dmd . 7 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
7
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Duchenne Muscular Dystrophy Dmd

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Catalyst Pharms 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating duchenne muscular dystrophy dmd . Each bar = one year. Y-axis scaled to peak year (3 patents).

3
29
1
33
3
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Agamree
VAMOROLONE
 Catalyst Pharms 7 62 — 2029-05-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10857161 Agamree method of use 76 2029-05-28
8334279 Agamree method of use 76 2029-05-28
12201639 Agamree method of use 75 2040-03-17
11690853 Agamree method of use 70 2033-03-07
11471471 Agamree method of use 70 2040-03-17
11833159 Agamree formulation 56 2029-05-28
11382922 Agamree composition of matter 12 2040-07-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11382922 Agamree composition of matter 12 2040-07-16
11833159 Agamree formulation 56 2029-05-28
11471471 Agamree method of use 70 2040-03-17
11690853 Agamree method of use 70 2033-03-07
12201639 Agamree method of use 75 2040-03-17
8334279 Agamree method of use 76 2029-05-28
10857161 Agamree method of use 76 2029-05-28

Related